The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Open accessAbstract
There is a need to improve treatments for metastatic breast cancer. Here, we show the activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in a MMTV-CreBrca1f/fTrp53+/− mouse model of breast cancer. When treated with the pan-class IA PI3K inhibitor NVP-BKM120, tumor doubling was delayed from 5 to 26 days. NVP-BKM120 reduced AKT phosphorylation, tumor cell proliferation, and angiogenesis. Resistant tumors maintained suppression of AKT phosphorylation but exhibited activation of the MAPK pathway at the “pushing margin.” Surprisingly, PI3K inhibition increased indicators of DNA damage, poly-ADP-ribosylation (PAR), and γ-H2AX, but decreased Rad51 focus formation, suggesting a critical role of PI3K activity for Rad51 recruitment. The PARP inhibitor olaparib alone attenuated tumor growth modestly; however, the combination of NVP-BKM120 and olaparib delayed tumor doubling to more than 70 days in the mouse model and more than 50 days in xenotransplants from human BRCA1-related tumors, suggesting that combined PI3K and PARP inhibition might be an effective treatment of BRCA1-related tumors. Significance: Current treatment options for triple-negative breast cancer are limited to chemotherapeutic regimens that have considerable toxicity and are not curative. We report here that the combination of a PI3K inhibitor with a PARP inhibitor provides in vivo synergy for treatment of an endogenous mouse model for BRCA1-related breast cancers, making this a candidate combination to be tested in human clinical trials. Cancer Discov; 2(11); 1048–63. ©2012 AACR. Read the Commentary on this article by Rehman et al., p. 982. This article is highlighted in the In This Issue feature, p. 961
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
BRCA1-induced Apoptosis Involves Inactivation of ERK1/2 Activities
Yan, Y., Haas, J. P., Kim, M., Sgagias, M. K., & Cowan, K. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201147200 · Cited by 50
RetractedTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Self-citationAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Self-citationHickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
Yuan, M., Breitkopf, S. B., Yang, X., & Asara, J. M. (2012) · Nature Protocols · doi:10.1038/nprot.2012.024 · Cited by 1,117
Self-citationPoly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia
Eliasson, M. J. L., Sampei, K., Mandir, A. S., Hurn, P. D., Traystman, R. J., Bao, J., Pieper, A., Wang, Z.-Q., Dawson, T. M., Snyder, S. H., et al. (1997) · Nature Medicine · doi:10.1038/nm1097-1089 · Cited by 1,018
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
Self-citationAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 2×
“The upregulation of compensatory pathways in response to tumor cell treatments with inhibitors of mitogenic signaling is now a well-known phenomenon (31).”
BackgroundSelf-citationRottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion
Ha, H. C., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13978 · Cited by 907
Xu, X., Wagner, K.-U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L., Wynshaw-Boris, A., & Deng, C.-X. (1999) · Nature Genetics · doi:10.1038/8743 · Cited by 758
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 583
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
Cre-mediated gene deletion in the mammary gland
Wagner, K.-U., Wall, R. J., St-Onge, L., Gruss, P., Wynshaw-Boris, A., Garrett, L., Li, M., Furth, P. A., & Hennighausen, L. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.21.4323 · Cited by 518
Gayther, S. A., Warren, W., Mazoyer, S., Russell, P. A., Harrington, P. A., Chiano, M., Seal, S., Hamoudi, R., van Rensburg, E. J., Dunning, A. M., et al. (1995) · Nature Genetics · doi:10.1038/ng1295-428 · Cited by 496
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
Yuan, S. F., Lee, S. Y., Chen, G., Song, M., Tomlinson, G. E., & Lee, E. Y.-H. P. (1999) · PubMed · Cited by 474
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Self-citationFox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C., & Harris, A. L. (1995) · The Journal of Pathology · doi:10.1002/path.1711770310 · Cited by 436
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Zingarelli, B., Salzman, A. L., & Szabó, C. (1998) · Circulation Research · doi:10.1161/01.res.83.1.85 · Cited by 334
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Tomlinson, G. E., Chen, T. T., Stastny, V., Virmani, A. K., Spillman, M. A., Tonk, V. S., Blum, J. L., Schneider, N. R., Wistuba, I. I., Shay, J. W., et al. (1998) · PubMed · Cited by 294
Masutani, M., Suzuki, H., Kamada, N., Watanabe, M., Ueda, O., Nozaki, T., Jishage, K.-I., Watanabe, T., Sugimoto, T., Nakagama, H., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2301 · Cited by 286
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C., van der Heijden, I., van der Gulden, H., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 262
Molecular cytogenetic analysis of 11 new breast cancer cell lines
Forozan, F., Veldman, R., Ammerman, C. A., Parsa, N. Z., Kallioniemi, A., Kallioniemi, O.-P., & Ethier, S. P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6695007 · Cited by 219
Brodie, S. G., Xu, X., Qiao, W., Li, W.-M., Cao, L., & Deng, C.-X. (2001) · Oncogene · doi:10.1038/sj.onc.1204929 · Cited by 188
Schnell, C. R., Stauffer, F., Allegrini, P. R., O'Reilly, T., McSheehy, P. M. J., Dartois, C., Stumm, M., Cozens, R., Littlewood-Evans, A., García-Echeverría, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1044 · Cited by 174
Resistance to Acute Septic Peritonitis in Poly(ADP-ribose) Polymerase-1-Deficient Mice
Soriano, F. G., Liaudet, L., Szab??, ?., Vir??g, L., Mabley, J. G., Pacher, P., & Szab??, C. (2002) · Shock · doi:10.1097/00024382-200204000-00008 · Cited by 172
Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair
Kumar, A., Fernandez-Capetillo, O., & Carrera, A. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914242107 · Cited by 165
Negative Regulation of AKT Activation by BRCA1
Tao, X., Ohashi, A., Huang, Y., Pandita, T. K., Ludwig, T., Powell, S. N., & Yang, Q. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-3009 · Cited by 134
Razandi, M., Pedram, A., Rosen, E. M., & Levin, E. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5900-5913.2004 · Cited by 121
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
Yuan, T. L., Choi, H. S., Matsui, A., Benes, C. H., Lifshits, E., Luo, J., Frangioni, J. V., & Cantley, L. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804123105 · Cited by 112
Self-citationDistinction between hereditary and sporadic breast cancer on the basis of clinicopathological data
van der Groep, P., Bouter, A., van der Zanden, R. A., Siccama, I., Menko, F. H., Gille, J. J. P., van Kalken, C. K., van der Wall, E., Verheijen, R. H. M., & van Diest, P. J. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.032151 · Cited by 101
Maor, S., Yosepovich, A., Papa, M. Z., Yarden, R. I., Mayer, D., Friedman, E., & Werner, H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.07.019 · Cited by 85
Collins, L. C., Martyniak, A., Kandel, M., et al. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819c1c93 · Cited by 81
Burga, L. N., Hu, H., Juvekar, A., Tung, N., Troyan, S. L., Hofstatter, E. W., & Wulf, G. M. (2011) · Breast Cancer Research · doi:10.1186/bcr2850 · Cited by 75
Self-citationNeuhausen, S. L., Brummel, S. S., Ding, Y. C., Singer, C. F., Pfeiler, G., Lynch, H. T., Nathanson, K. L., Rebbeck, T. R., Garber, J. E., Couch, F. J., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2414 · Cited by 58
Molecular and Functional Imaging of Breast Cancer
Tafreshi, N. K., Kumar, V., Morse, D. L., & Gatenby, R. A. (2010) · Cancer Control · doi:10.1177/107327481001700302 · Cited by 50
Shukla, V., Coumoul, X., Cao, L., Wang, R.-H., Xiao, C., Xu, X., Andò, S., Yakar, S., LeRoith, D., & Deng, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4570 · Cited by 49
Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers
Neuhausen, S. L., Brummel, S. S., Ding, Y. C., Steele, L., Nathanson, K. L., Domchek, S. M., Rebbeck, T. R., Singer, C. F., Pfeiler, G., Lynch, H. T., et al. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1336 · Cited by 19
Targeting Cell Metabolism in Cancer Patients
Heiden, M. G. V. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001210 · Cited by 18
Cited by
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“…examining the mechanism by which PI3K inhibitors impact the progression of BRCA1/TP53 mutant tumors, Juvekar et al. demonstrated that synthesis of ribose and a set of glycolytic intermediates were impaired in response to PI3K inhibition, with lesser effects of AKT inhibitors (Juvekar et al., 2012).”
Self-citationThe PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Metadata
- Authors
- Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., Nardella, C., Pandolfi, P. P., Baselga, J., Scully, R., Asara, J. M., Cantley, L. C., & Wulf, G. M.
- Venue
- Cancer Discovery
- Published
- 2012-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 1048-1063
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2120806256
- Cited by
- 465
- References
- 48
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.